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ABSTRACT 22 
Background: Diabetes is prevalent in Kuwait. We aimed to assess the level of glycemic control in 23 
Kuwaiti adults with diabetes.  24 
Method: The World Health Organization’s STEPS non-communicable disease risk factor survey 25 
was conducted in Kuwait in 2014. Participants’ demographics, medical history, physical 26 
measurements and blood biochemistry were assessed. A total of 2,561 Kuwaiti men and women 27 
aged 18-69 years completed all three survey steps. Glycemic control in 278 individuals with 28 
diabetes who were on glucose-lowering medication was determined using the US National 29 
Institutes of Health guidelines of fasting plasma glucose (FPG) ≤7.2mmol/l and the American 30 
Diabetes Association guidelines of glycated hemoglobin (HbA1c) <7% (53 mmol/mol). 31 
Results: Adequate glycemic control in people with drug-treated diabetes was 34.5% when 32 
determined by HbA1c, 37.8% when determined by FPG level, and 24.5% when both criteria were 33 
met. Mean body-mass index and fasting serum triglycerides were significantly higher, and serum 34 
high-density lipoprotein-cholesterol were significantly lower in individuals with an inadequate 35 
glycemic control than in those with adequate control. Women with diabetes were almost twice 36 
as likely to have inadequate HbA1c levels as men with diabetes (OR, 1.9, [95% CI, 1.03, 3.5]). 37 
Conclusions: Glycemic control in Kuwaiti people with treated diabetes is low. A systemic, multi-38 
disciplinary public health approach is needed to improve diabetes education and adherence to 39 
treatment.  40 
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INTRODUCTION  42 
Diabetes is a growing worldwide health concern and the prevalence is particularly high in 43 
the Middle East and North Africa (MENA). According to International Diabetes Federation, 44 
diabetes prevalence is 8.8% globally and 10.8% in the MENA region [1]. In Kuwaiti adults aged 18 45 
to 69 years, the age-adjusted prevalence of diabetes is 18.8% according to the latest survey [2]. 46 
The prevalence of diabetes-associated disorders in Kuwait such as obesity, hypertension and 47 
dyslipidemia is also high [3, 4]. Additionally, the socioeconomic burden of diabetes in Kuwait is 48 
high; the estimated cost of treating diabetes and its complications in Kuwait is $2,000 annually 49 
per person with diabetes [5].   50 
The effective management of diabetes is essential for maintaining health and quality of 51 
life, preventing the progression to complications due to diabetes and avoiding excessive costs of 52 
treating people with diabetes. Healthy diet, physical activity and pharmaceutical interventions, 53 
in combination, are the most common approaches for diabetes management [6-8]. Effective 54 
diabetes management is primarily defined by adequate glycemic control, as measured by 55 
glycated hemoglobin (HbA1c) and/or fasting plasma glucose (FPG) levels [9, 10]. It is also 56 
important to manage dyslipidemia, hypertension, smoking and other risk factors associated with 57 
the development of complications and increased mortality [11]. Uncontrolled glycemic levels 58 
increase the risk of micro- and macrovascular complications and several other complications in 59 
various organs [12]. However, the proportion of people with diabetes achieving desired glycemic 60 
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targets is generally poor [13]. In the countries of the Arabian Gulf, adequate glycemic control 61 
ranges from 15% to 41% [14], but population-based studies in the region are rare.   62 
A World Health Organization (WHO) STEPwise non-communicable disease health survey 63 
was conducted in Kuwait on a representative sample of Kuwaiti adults in 2014 [4]. We have 64 
previously reported on the prevalence of diabetes [2] and obesity [3] in this population. This 65 
study reports on the level of glycemic control in Kuwaiti adults under treatment for diabetes.  66 
METHODS  67 
Survey design 68 
A cross-sectional population health survey entitled the Eastern Mediterranean 69 
Approaches to Non-Communicable Diseases (EMAN) was conducted in Kuwait between March 70 
and September 2014. The survey was conducted by the Ministry of Health and supported by the 71 
WHO, as has been previously described [2]. Briefly, data was collected using the STEPwise 72 
approach to Surveillance methodology (STEPS) [4, 15] which consisted of 3 consecutive steps: 1) 73 
demographics and medical history, 2) physical measurements and 3) blood biochemistry. In Step 74 
1, participants self-reported their medical history and medication, including insulin, although no 75 
distinction was made between type 1 and type 2 diabetes.  76 
The Public Authority for Civil Information prepared a random national sample of Kuwaiti 77 
citizens aged 18 to 69 years from eight age- and sex-stratified groups (18-29, 30-44, 45-59 and 78 
60-69 years). The survey target sample was 4,391 participants (inflated for expected non-79 
participation) and 3,915 participants completed the first two steps. The number of participants 80 
who completed all three steps, including anthropometric measures and obtaining a valid FPG and 81 
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HbA1c measurements, was 2,561. The age-standardized prevalence of diabetes in this population 82 
was 18.8%, as has been previously reported [2]. The number of individuals with diabetes who 83 
self-reported receiving glucose-lowering drug treatment for diabetes was 278. There were 15 84 
people who self-reported having diabetes but were not receiving drug treatment for diabetes. 85 
They were not included in this analysis that evaluated the efficacy of treatment.  86 
Data collection 87 
Height and weight were measured using the electronic Growth Management Scale. Body 88 
mass index (BMI) was calculated by dividing a person’s weight in kilograms by the square of 89 
height in meters. Waist and hip circumference were determined using a Miotape. Central 90 
adiposity was determined using waist-to-hip ratio (WHR). Of the 278 individuals with diabetes in 91 
this study, 264 had a recorded BMI and 253 had a recorded waist-hip ratio. A mercury 92 
sphygmomanometer with a universal cuff was used on the right arm in a sitting position to 93 
determine blood pressure (BP). Participants’ BP was measured three times and they rested for 3 94 
minutes between each measurement. The mean of the second and third measurements was 95 
taken for analysis. Venous blood samples were collected after a 12 hour fast in sodium fluoride 96 
vacutainer and serum separator tubes for lipid profile and FPG measurements. Whole blood was 97 
sampled in EDTA tubes for HbA1c measurements. Blood samples were immediately centrifuged 98 
after sample collection and examined by an Auto-analyzer Architect within 6 hours. Blood 99 
biochemistry analysis was conducted by the laboratory of the Kuwait Cancer Control Center 100 
Clinical Laboratory using standard clinical laboratory techniques and quality control procedures.   101 
 102 
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 104 
Standards 105 
Diabetes was defined as FPG >7.0 mmol/l or HbA1c ≥6.5% (48 mmol/mol) or use of 106 
glucose lowering drugs [16]. Treated diabetes was determined by self-reported current 107 
treatment with physician-prescribed glucose lowering drugs. The criteria used for adequate 108 
control of diabetes were the National Institute of Health (NIH) guidelines for FPG ≤7.2 mmol/l 109 
(≤130 mg/dl) [10] and the American Diabetes Association (ADA) guidelines for HbA1c <7% (53 110 
mmol/mol) [9]. Obesity was defined as BMI ≥30 kg/m2 and overweight was defined as BMI 25-111 
29.9 kg/m2 [17]. Elevated WHR was defined as ≥0.9 for men and ≥0.85 for women.  112 
Statistical analysis 113 
Statistical analysis was performed using GraphPad Prism 8 and IBM SPSS Statistics version 114 
25. Two-tailed t-tests, the Chi-square test and the Chi-square test for trend were used as 115 
appropriate. Binary logistic regression models were used to assess associations between 116 
sociodemographic, lifestyle and medical factors and glycemic control. Statistical significance was 117 
determined by p<0.05.  118 
Ethical Considerations  119 
This study was approved by the Ministry of Health Standing Ethics Committee for the 120 
Coordination of Medical and Health Research. Written informed consent was obtained from each 121 
participant. The study adhered to the Declaration of Helsinki ethical standards.   122 
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RESULTS 124 
Treatment was received by 94.9% (278/293) of individuals with known diabetes. Of the 125 
278 individuals with diabetes under treatment, 60% were women and 40% were men (Table 1). 126 
Mean age was 51.1 years, mean BMI was 33.1 kg/m2 and mean systolic and diastolic blood 127 
pressure was 129 mmHg and 82 mmHg, respectively. Insulin was prescribed to 45.7% of the 128 
diabetic patients (127/278); 52.2% were also receiving anti-hypertensive medication (145/278) 129 
and 47.1% were receiving lipid-lowering medication (131/278). Over two thirds (180/264) were 130 
obese and 11.2% (31/278) were smokers. Over 70% had an elevated waist-hip ratio (178/253). 131 
Men had significantly higher mean diastolic blood pressure (p=0.02) and smoking prevalence 132 
(p<0.0001) than women. Women were more obese (p=0.01), had significantly higher BMI 133 
(p=0.002) and fasting serum HDL levels (p=0.02) than men. 134 
Approximately a third (34.5%, 95% CI 31.6, 37.5) of Kuwaitis with diabetes under glucose-135 
lowering treatment had adequate glycemic control as measured by HbA1c (<7%) (Figure 1A). An 136 
almost similar percentage (37.8%, 95% CI 34.8, 40.8) had adequate FPG levels (≤7.2mmol/l). Less 137 
than a quarter (24.5%, 95% CI 21.9, 27.3) of the patients under treatment had both adequately 138 
controlled HbA1c and FPG levels; 10% (28/278) had controlled HbA1c only and 13% (37/278) had 139 
controlled FPG only (Figure 1B). Mean BMI (p=0.0005) and fasting serum triglycerides (p=0.02) 140 
were significantly lower and fasting high-density lipoprotein (HDL, p=0.03) was significantly 141 
higher in Kuwaitis with an adequate HbA1c compared with those with an uncontrolled HbA1c 142 
8 
(Table 2). Mean BMI (p=0.03) and fasting triglycerides (p=0.0003) were also significantly lower in 143 
individuals with adequate FPG levels.  144 
The proportion of men with diabetes with HbA1c <7% was 43.2%, significantly higher than 145 
the 28.7% found in women with diabetes (p=0.013, Table 3). Patients treated with insulin also 146 
had lower proportion of adequate glycemic control (25.2%) than patients treated with oral 147 
glucose-lowering drugs only (42.5%, p=0.003). Except for individuals with a normal BMI and men 148 
with normal WHR, every population subgroup had a majority of people with diabetes with poor 149 
glycemic control. Kuwaiti women with diabetes were almost twice as likely to have poor HbA1c 150 
levels as men (Odds Ratio, OR = 1.9, p=0.04) (Table 4). Patients on insulin were also twice as likely 151 
to have both poor HbA1c (OR = 2.7, p=0.001) and FPG levels (OR = 1.9, p=0.02) as those treated 152 
with oral drugs. Patients who were obese or had an elevated waist-to-hip ratio tended to have 153 
higher inadequate HbA1c levels, although this increase did not reach statistical significance.  154 
DISCUSSION  155 
In this cross-sectional survey from 2014, we found that although the proportion of drug 156 
treatment for diabetes was high (95%) among people with known diabetes, most Kuwaiti adults 157 
with diabetes under glucose-lowering drug treatment had poor glycemic control. Only 35% had 158 
adequate HbA1c levels and 38% had adequate FPG levels. Almost half of diabetic patients were 159 
prescribed insulin, indicating that treatment with oral antidiabetic drugs had not been successful 160 
for reasons unknown in this survey. Mean BMI and fasting serum triglycerides were significantly 161 
higher and fasting serum HDL was significantly lower in individuals with poor glycemic control. 162 
Adequate glycemic control was significantly higher in men with diabetes compared with women. 163 
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Although glycemic control in Kuwait overall was found to be low in this study, when 164 
comparing our results to previous studies, it appears to have been improving with time. 165 
Approximately 30% of patients attending a specialist diabetes medical and research center in 166 
Kuwait between 2011 and 2014 had an HbA1c <7% [18]. A study analyzing data from the Kuwait 167 
Diabetes Register reported that only 26% of Kuwaiti diabetic patients had an HbA1c <7% in 2012 168 
[19], while in Kuwait in 2010 glycemic control was reportedly between 19% [20, 21] and 21% [22]. 169 
This apparent improvement in glycemic control is in keeping with other findings from the Arabian 170 
Gulf countries. In Saudi Arabia, adequate glycemic control improved from 21% in 2004 [23] to 171 
32% in 2013 [24], in Oman from 23% in 2007 [25] to 35% in 2013 [26], in Bahrain from 15% in 172 
2004 [27] to 32% in 2010 [28], and in the UAE from 31% in 2006  [29] to 38% in 2016 [30]. In 173 
Qatar, glycemic control was 31% in 2015 [31]. 174 
Despite the improvement, levels of glycemic control in the Arabian Gulf countries falls 175 
behind Europe and North America [21]. In the US, almost 60% of adults with diabetes achieved 176 
HbA1c <7% in 2010 [32]. Glycemic control differed by ethnicity; non-Hispanic whites achieved 177 
higher levels of glycemic control than non-Hispanic blacks and Mexican Americans [32]. In 178 
Europe, a cross-country analysis reported glycemic control to be over 50%, although there was 179 
considerable inter-country variation [33]. In Asia, glycemic control was reported to be 45% in 180 
Japan [34], 39% in South Korea [35], 32% in China [36], 31% in India [37], 23% in Bangladesh [38], 181 
22% in Malaysia [39] and 15% in the Philippines [40]. In a population survey in Mauritius, glycemic 182 
control in people with diabetes based on HbA1c was 19% in 2009, and had improved to 22% in 183 
2015, but still remained poor [41]. A recent analysis of data from diabetes clinics across nine 184 
countries outside North America and Europe did not find improvement in glycemic control from 185 
10 
2006 to 2015 on average [42]. However, there was heterogeneity among the countries: the 186 
proportion of patients who reached the target of HbA1c <7% increased in Argentina, India, Japan, 187 
Russia and South Africa, but not in Australia, Hong Kong, Saudi Arabia and Uganda. Among all the 188 
clinical services, South Africa had the lowest glycemic control with only 10% and 17% in 2006 and 189 
2015, respectively. This study also showed that the introduction of newer classes of glucose-190 
lowering drugs did not improve glycemic control. 191 
Being overweight or obese is associated with poor glycemic control in people with 192 
diabetes [43]. In this study, over two thirds of individuals treated for diabetes were obese. The 193 
only subgroup with over 50% of adequate glycemic control comprised individuals with normal 194 
weight (BMI <25kg/m2) and in men with normal WHR. The prevalence of overweight and obesity 195 
is high in Kuwait [3] and the surrounding region [44]. High calorie diets, sugar-sweetened 196 
beverages, low physical activity, sedentary lifestyle, genetic factors and some cultural barriers 197 
are among contributing factors to the obesity epidemic in the Middle East [45].  198 
We found glycemic control to be less in women than men, findings consistent with recent 199 
studies on type 2 diabetes in South Korea [35] and type 1 diabetes in Italy [46]. Although the 200 
prevalence of diabetes is higher in Kuwaiti men than women [2], the prevalence of obesity and 201 
mean BMI are higher in Kuwaiti women, and Kuwaiti women are also less physically active than 202 
men [3]. In this study, obesity levels and mean BMI  were significantly higher in Kuwaiti women 203 
being treated for diabetes than in men, which suggest that a targeted high-risk obesity 204 
prevention approach may benefit women with concurrent obesity and poor glycemic control.  205 
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Hypertension is also highly prevalent in Kuwait in general [4] and in Kuwaiti people with 206 
diabetes [47]. Over half of individuals receiving glucose lowering drug treatment in this study 207 
were also receiving antihypertensive drug treatment. Hypertension is associated with worsening 208 
complications of diabetes, and improvement in blood pressure leads to a reduction in both 209 
macrovascular and microvascular complications in patients with diabetes [48]. Almost half of 210 
people with diabetes in this study were also receiving treatment for dyslipidemia, and elevated 211 
fasting triglycerides and low HDL levels were significantly more common in those with poor 212 
glycemic control. Poor lipid profiles have been previously reported to be associated with poor 213 
glycemic control in other studies [34, 49, 50].  214 
Other factors that contribute to poor glycemic control are poor diabetes education and 215 
poor adherence to treatment. There is a general lack of diabetes education in the Middle East 216 
[51]. In Kuwait, most diabetic patients do not adhere to diet or exercise advice [52], and over a 217 
quarter of patients do not fully adhere to their prescribed glucose lowering medication [53]. 218 
Many patients do not consider diabetes to be a chronic condition with serious health implications 219 
[54]. Treating and controlling co-morbidities, as well as improving education and adherence to 220 
treatment, are essential to improving glycemic control. Recent studies have also highlighted the 221 
benefit of benchmarking and target setting in improving diabetes care [55, 56].  222 
The WHO STEPS study strengths included the representative, population-based sample 223 
and its standardized measurement techniques. However, in this study only Kuwaiti nationals 224 
were surveyed, whereas Kuwaiti has a large, multi-ethnic, expatriate majority [57]. Previous 225 
studies on glycemic control in Kuwait have only included Kuwaiti nationals as well [19, 20, 22]. 226 
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Diabetes prevalence among expatriates in Kuwait is reportedly to be even higher than amongst 227 
Kuwaiti nationals [47]. The WHO STEPS survey did not distinguish between type 1 and type 2 228 
diabetes, but it can be assumed that the proportion of people with type 1 diabetes is likely less 229 
than 10% of all individuals with diabetes in this study. Other limitations include the lack of 230 
longitudinal measurements or measures of adherence to medication and lifestyle treatments. 231 
We did not have information about the names of drugs and their doses, and therefore we could 232 
not assess the quality of specific prescribed treatments. Nonetheless, this study showed that the 233 
introduction of newer classes of glucose-lowering drugs did not improve glycemic control (Table 234 
x).  235 
Many factors contribute to the poor glycemic control levels found in this study in Kuwait. 236 
Of note, the very high prevalence of treatment among known diabetes in this study (95%) 237 
suggests that the diabetes population has a very high degree of access to diabetes services in 238 
Kuwait, although glycemic control should be improved. The Ministry of Health can use these data 239 
to tailor interventions focused on prescribing physicians and people with diabetes, to improve 240 
glycemic control from both directions. Also, in view of the extraordinarily high prevalence of 241 
diabetes in Kuwait, a holistic public health approach is needed to decrease the prevalence of 242 
diabetes and associated co-morbidities and to better educate people with diabetes on the 243 
importance of maintaining a healthy diet, physical activity and adherence to prescribed 244 
medication. The next STEPS survey in Kuwait is planned for 2020, and it will be possible to assess 245 
if improvements in glycemic control continues among people with diabetes. 246 
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Table 1: Demographic and selected clinical information of 278 Kuwaiti patients with treated diabetesⱡ 
Participant Characteristics  Total  Men Women  
Patients, n (row %) 278  111 (40) 167 (60) p 
Age (years) 51.1  
± 11.7 
 50.1  
± 12 
51.8  
± 11.4 
0.23 
BMI (kg/m2) 33.1  
± 6.65 
 31.6  
± 5.6 
34.2  
± 7.08 
0.002 
Systolic blood pressure (mmHg) 129  
± 15.1 
 131  
± 15.2 
128  
± 14.9 
0.17 
Diastolic blood pressure (mmHg) 82  
± 9.7 
 83  
± 10.9 
80  
± 8.6 
0.02 
Fasting plasma glucose (mmol/L) 9.42  
± 4.26 
 9.25  
± 4.16 
9.54  
± 4.33 
0.59 
HbA1c (%) 8.17  
± 2.24 
 7.85  
± 2.21 
8.38  
± 2.24 
0.06 
Fasting serum HDL (mmol/L) 1.18  
± 0.28 
 1.1  
± 0.26 
1.24  
± 0.28 
<0.0001 
Fasting serum LDL 2.96 
 ± 0.97 
 2.87  
± 0.85 
3.01  
± 1.04 
0.24 
Fasting serum triglycerides (mmol/L) 1.84  
± 1.23 
 2.01  
± 1.57 
1.73 
 ± 0.93 
0.06 
Fasting serum total Cholesterol (mmol/L) 5.0  
± 1.12 
 4.9  
± 1.02 
5.0  
± 1.19 
0.24 
Waist-hip ratio (WHR) 0.91  
± 0.09 
 0.94  
± 0.1 
0.89  
± 0.07 
<0.0001 
Obesity (%) 68.2%  59.4% 74.1% 0.01 
Elevated WHR (%) 70.4%  70% 70.6% 0.92 
Smoking (%) 11.2%  27% 0.6% <0.0001 
Use of insulin (%) 45.7%  44.1% 46.7% 0.67 
Use of anti-hypertensive medication (%) 52.2%  45.9% 56.3% 0.09 
Use of lipid lowering medication (%) 47.1%  45% 48.5% 0.57 
ⱡValues represent mean ± standard deviation, or frequencies. Obesity defined as a ≥BMI 30kg/m2. Elevated waist-hip 
ratio defined as ≥0.9 for men and ≥0.85 for women. P values assessed by two-tailed t-tests or the Chi-square test as 
appropriate. Of the 278 diabetes patients in this study, 264 had a recorded BMI and 253 had a recorded waist-hip 
ratio. 
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Figure 1: (A) The proportion of people with treated diabetes achieving adequate glycemic 
control as measured by HbA1c, FPG and both. n=278. (B) A Venn diagram of the number of 
people with diabetes achieving glycemic control as measured by HbA1c and FPG. n=133 
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Table 2: Demographic and selected clinical parameters of individuals with treated diabetes with and without adequate controlⱡ  
Participant Characteristics    
HbA1c <7% 
 
HbA1c ≥7% 
p  FPG ≤7.2 
mmol/l 
FPG >7.2 
mmol/l 
p 
Patients, n (n=96) (n=182) -  (n=105) (n=173) - 
Age (years) 50.1 ± 12.7 51.6 ± 11.1 0.29  49.8 ± 12.5 51.8 ± 11.1 0.17 
BMI (kg/m2) 31.2 ± 6.11 34.2 ± 6.71 0.0005  32 ± 6 33.8 ± 6.96 0.03 
Systolic blood pressure (mmHg) 128 ± 16 130 ± 14.5 0.36  128 ± 14.9 130 ± 15.2 0.25 
Diastolic blood pressure (mmHg) 82 ± 9.74 81 ± 9.74 0.42  82 ± 9.71 82 ± 9.79 0.99 
Fasting plasma glucose (mmol/L) 6.5 ± 1.96 11.0 ± 4.33 <0.0001  5.7 ± 0.93 11.7 ± 3.86 <0.0001 
HbA1c (%) 6.0 ± 0.59 9.3 ± 1.87 <0.0001  6.6 ± 1.35 9.1 ± 2.14 <0.0001 
Fasting serum HDL (mmol/L) 1.23 ± 0.31 1.16 ± 0.26 0.03  1.21 ± 0.26 1.17 ± 0.29 0.28 
Fasting serum LDL 2.87 ± 0.71 3.00 ± 1.08 0.29  2.98 ± 1.19 2.94 ± 0.82 0.71 
Fasting serum triglycerides 
(mmol/L) 
1.61 ± 0.87 1.97 ± 1.37 0.02  1.5 ± 0.77 2.05 ± 1.41 0.0003 
Total Cholesterol (mmol/L) 4.9 ± 0.87 5.0 ± 1.23 0.21  4.9 ± 1.32 5.0 ± 0.98 0.27 
Waist-hip ratio - Men 0.93 ± 0.14 0.95 ± 0.06 0.25  0.94 ± 0.14 0.94 ± 0.06 0.93 
Waist-hip ratio - Women 0.87 ± 0.07 0.89 ± 0.07 0.2  0.88 ± 0.07 0.89 ± 0.08 0.21 
ⱡValues represent mean ± standard deviation or frequencies. P values assessed by two-tailed t-tests.  
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Table 3: Frequency of glycemic control by demographic and clinical informationⱡ 
Characteristic Prevalence of Glycemic Control (%) 
 HbA1c <7% p FPG ≤7.2 mmol/l p 
All 34.5%   37.8%   
     
Sex   0.01   0.44 
 Men 43.2%   40.5%   
 Women 28.7%   35.9%   
     
Age   0.56   0.22 
 18-29 44.4%   50.0%   
 30-44 37.3%   43.1%   
 45-59 31.4%   35%   
 60-69 36.2%   36.2%   
     
Use of insulin   0.003   0.14 
 Yes 25.2%   33.1%   
 No 42.5%   41.7%   
     
Anti-hypertensive medication   0.63   0.95 
 Yes 35.9%   37.9%   
 No 33.1%   37.6%   
     
Lipid-lowering medication   0.57   0.90 
 Yes 32.8%   38.2%   
 No 36.1%   37.4%   
     
Smoking   0.19   0.15 
 Smokers 45.2%   25.8%   
 Non-smokers 33.2%   39.3%   
     
Obesity   0.07   0.60 
 Normal weight 54.5%   40.9%   
 Overweight 35.5%   41.9%   
 Obese 32.2%   37.8%   
     
Waist-Hip Ratio   0.06   0.62 
 Normal 44.0%   42.7%   
 Elevated 31.5%   39.3%   
     
Waist-Hip Ratio – Men   0.004   0.22 
 Normal 66.7%   53.3%   
 Elevated 35.7%   40.0%   
     
Waist-Hip Ratio – Women     0.98   0.70 
 Normal 28.9%   35.6%   
 Elevated 28.7%   38.9%   
ⱡP values assessed Chi-square test of Chi-square test for trend as appropriate. Normal weight defined as BMI 
≥25 kg/m2, overweight defined as BMI 25-29.99kg/m2 and obesity defined as a BMI >30kg/m2. Elevated 
waist-hip ratio defined as ≥0.9 for men and ≥0.85 for women.   
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Table 4: Logistic regression models with glycemic control as the dependent variableⱡ  
   Odds Ratio of HbA1c ≥7%  Odds Ratio of FPG >7.2 mmol/l 
Characteristic Comparison beta OR CI (95%) P  Beta OR CI (95%) p 
Women  Men 0.64 1.9 [1.0, 3.5] 0.04  0.41 1.5 [0.8, 2.7] 0.16 
Age ≥50 years Age<50 years -0.25 0.8 [0.3, 2.0] 0.61  0.88 2.4 [0.9, 6.4] 0.08 
Obesity (BMI ≥30kg/m2) Non-Obese 0.44 1.6 [0.8, 2.9] 0.16  0.13 1.1 [0.6, 2.0] 0.67 
Elevated waist-hip ratio Normal WHR 0.43 1.5 [0.9, 2.8] 0.15  0.01 1.0 [0.6, 1.8] 0.97 
Current Smoking Non-Smoking 0.32 1.5 [0.8, 2.5] 0.30  0.39 1.5 [0.8, 2.6] 0.17 
Use of insulin Non-use 0.98 2.7 [1.5, 4.7] 0.001  0.62 1.9 [1.1, 3.2] 0.02 
Use of antihypertensive drugs Non-use -0.47 0.6 [0.3, 1.2] 0.14  -0.041 1.0 [0.5, 1.7] 0.89 
Use of lipid lower drugs Non-use 0.24 1.3 [0.7, 2.6] 0.42  -0.032 1.0 [0.6, 1.7] 0.91 
ⱡOR=odds ratio, CI=confidence interval. Full model, n = 251.  
 
 
 
